Journal · Repair
The Immune Rules Most Peptide Protocols Ignore
The short answer
Most repair protocols are built around the structural compounds people have heard of: BPC-157, TB-500, GHK-Cu. The immune system decides whether those compounds get to do anything. If the tissue is stuck in an inflammatory state, the repair signal lands on cells that can’t use it.
Questions this article answers
- Why is my BPC-157 not working?
- What are immune-modulating peptides?
- Should you take anti-inflammatories right after an injury?
- Are these peptides FDA approved?
The mistake almost everyone makes
Picture a tendon that has been sore for eight months. Someone reads about BPC-157, adds TB-500 because the forums pair them, and waits. Six weeks later nothing has changed, and the conclusion is that peptides don’t work.
Section 2.8 of Regenerative Resilience names this as the most common error in regenerative protocol design: putting structural repair compounds into tissue that is immunologically unprepared to use them. If inflammation hasn’t resolved, if macrophages are stuck in their pro-inflammatory M1 mode, or if cytokines are chronically elevated and interfering with fibroblasts, structural compounds underperform. That’s biology, not bad luck.
So the first question isn’t which repair peptide? It’s what state is the immune system in, in the tissue I’m trying to repair?
Why the immune system runs the repair process
Macrophages are the pivot. Early after an injury they take an inflammatory role, clearing debris and damaged cells. Repair only moves forward when they switch to a resolving, rebuilding role (often shortened to M2) and start signalling fibroblasts, blood vessels and matrix. A 2016 review in Immunity describes macrophages as regulators of every stage of repair, and shows that when that switch goes wrong, the result is chronic inflammation or fibrosis instead of healthy tissue (reference 2).
That is why the book calls immune modulation foundational rather than an add-on. In many chronic cases, calming the immune environment is the intervention that makes structural repair possible at all.
Rule 1: Read the immune environment before choosing a structural compound
Chronic pain, slow healing and a history of flare-ups all point to an environment that is hostile to repair. The book lists objective markers a clinician can use to judge this, including CRP, IL-6, TNF-alpha and a full blood count with differential. The point isn’t the specific test. It’s that the decision is made from data about the tissue, not from whichever compound is trending.
Rule 2: Don’t silence the first 48 hours of inflammation
Early inflammation is doing a job. Neutrophils and M1 macrophages clear the wound and start the repair cascade, and aggressive anti-inflammatory intervention in the first 24 to 48 hours after an acute injury can interfere with it. In acute injuries, the framework holds immune-modulating compounds back until that early phase has run, generally 48 to 72 hours in, and uses them to support the M1-to-M2 transition rather than shut inflammation down.
Chronic cases flip the rule. When inflammation has run for months or years without resolving, immune regulation should start right away, because nothing structural will hold until it does.
Rule 3: Run immune and structural support together
This sounds like it contradicts Rule 1, and it doesn’t. Assessing the immune state comes first. Once the protocol exists, the book’s position is that immune-modulating and structural compounds usually work best running at the same time, not one strictly after the other. A calmer immune environment helps structural compounds work, and the tissue signals from structural repair (less debris, less oxygen starvation, better-organised matrix) help inflammation resolve. Each speeds up the other.
Rule 4: Match the compound to the specific immune problem
“Immune peptides” isn’t one category. The five compounds in the book each fit a different failure:
- KPV when NF-kB-driven cytokine overactivity is the main problem. In mouse models of colitis, KPV taken up through the gut transporter PepT1 reduced intestinal inflammation (reference 3).
- Thymosin Alpha-1 when regulatory T cell function and T cell maturation are impaired. It is the only compound in the book approved as a medicine in several countries, though not in the US.
- VIP when you need both immune calming and better blood flow to the site.
- LL-37 when barrier integrity and antimicrobial defence are concurrent priorities.
- ARA-290 when direct protection of stressed cells matters alongside anti-inflammatory signalling.
Using all five in every protocol isn’t precision. The book’s line on this is blunt: it’s complexity. Picking the one that matches the failure you’ve identified is what separates a designed protocol from a pile of compounds.
Questions people ask
Why is my BPC-157 not working?
One common reason is the tissue environment rather than the compound. Regenerative Resilience (pp. 74–75) explains that structural repair compounds underperform when inflammation hasn’t resolved or macrophages are stuck in a pro-inflammatory state. Other factors, such as poor blood supply and low cellular energy, can cap results too. A clinician can help work out which barrier applies.
What are immune-modulating peptides?
Peptides that shift how the immune system behaves rather than simply boosting or suppressing it. The five covered in Regenerative Resilience are KPV, Thymosin Alpha-1, VIP, LL-37 and ARA-290, and each works through a different mechanism.
Should you take anti-inflammatories right after an injury?
The early inflammatory phase clears damaged tissue and starts repair, and research on wound healing shows it is a necessary stage (reference 1). That’s why the book’s framework avoids aggressive anti-inflammatory intervention in the first 24 to 48 hours of an acute injury. Decisions about medication after an injury belong with a doctor.
Are these peptides FDA approved?
None of the five is FDA approved for tissue repair. In July 2026 an FDA advisory committee voted to recommend KPV for the list of substances pharmacies may compound, a non-binding step (reference 4). Rules change quickly and differ by country.
Where this comes from in our books
This article is the plain-language version. The book sections below go further, with full mechanism detail, evidence tiers and how each idea fits a complete protocol. Page numbers refer to the print editions.
Regenerative Resilience
Section 2.8, Integrating Immune Modulation into Regenerative Protocols · pp. 74–76
Regenerative Resilience
Section 2.7, Immune-Modulating Peptides: Mechanisms Overview · pp. 71–74
Read next
Put the framework to work
The free Protocol Builder applies the same category-first logic as the books, built from the same compound database.
Open the Protocol BuilderSee the book seriesReferences
- Eming SA, Martin P, Tomic-Canic M. Wound repair and regeneration: mechanisms, signaling, and translation. Sci Transl Med. 2014;6(265):265sr6. View sourceCited in Regenerative Resilience (p. 347)
- Wynn TA, Vannella KM. Macrophages in Tissue Repair, Regeneration, and Fibrosis. Immunity. 2016;44(3):450–462. View source
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178. View source
- National Community Pharmacists Association. FDA advisory committee nominates six peptides for pharmacies to compound. July 31, 2026. View source
How this article is maintained. Research and regulatory status change. We review our articles against current sources and update them as new information becomes available; the date at the top shows the last review.
Educational information only, not medical advice. Nothing in this article is a recommendation to use any compound or a dosing guide. Talk to a qualified clinician before starting, stopping or combining any compound.